Overdose deaths have reduced survival gains among people with HIV in British Columbia

Image: Naloxone at a needle exchange in Birmingham, UK. Nigel Brunsdon / nigelbrunsdon.com

Survival gains resulting from effective antiretroviral therapy are threatened by drug overdose deaths among people living with HIV, researchers reported this month at the 23rd International AIDS Conference (AIDS 2020: Virtual). A related study found that HIV-positive people who use drugs are also at greater risk of death due to acute infections.

"The unprecedented rise in overdose deaths among people living with HIV has considerably reduced the gains in life expectancy achieved through treatment as prevention, underscoring the importance of access to safe drug supply," Martin St-Jean of the British Columbia Centre for Excellence in HIV/AIDS told aidsmap.com.

British Columbia has been a pioneer in harm reduction in North America, having implemented the earliest needle exchange programmes in Canada in the late 1980s and opened North America’s first supervised injection facility, Vancouver's Insite, in 2003.

Nonetheless, drug overdose deaths have increased dramatically in the province since 2014, leading to the declaration of a public health emergency in 2016, the study authors noted as background.

Glossary

harm reduction

Harm reduction is a set of practical strategies and ideas aimed at reducing negative consequences associated with drug use (including safer use, managed use and abstinence). It is also a movement for social justice built on a belief in, and respect for, the rights of people who use drugs.

acute infection

The very first few weeks of infection, until the body has created antibodies against the infection. During acute HIV infection, HIV is highly infectious because the virus is multiplying at a very rapid rate. The symptoms of acute HIV infection can include fever, rash, chills, headache, fatigue, nausea, diarrhoea, sore throat, night sweats, appetite loss, mouth ulcers, swollen lymph nodes, muscle and joint aches – all of them symptoms of an acute inflammation (immune reaction).

treatment as prevention (TasP)

A public health strategy involving the prompt provision of antiretroviral treatment in people with HIV in order to reduce their risk of transmitting the virus to others through sex.

retention in care

A patient’s regular and ongoing engagement with medical care at a health care facility. 

exclusion criteria

Defines who cannot take part in a research study. Eligibility criteria may include disease type and stage, other medical conditions, previous treatment history, age, and gender. For example, many trials exclude women who are pregnant, to avoid any possible danger to a baby, or people who are taking a drug that might interact with the treatment being studied.

People with HIV may be at greater risk of dying from an overdose because of worse respiratory distress or HIV-related pulmonary or liver impairment, and they may face more barriers to access and retention in substance use treatment, the researchers suggested.

St-Jean's team assessed the impact of drug overdoses on life expectancy among people living with HIV in British Columbia and identified risk factors associated with increased overdose mortality.

They calculated overdose mortality and mortality due to other causes using the BC vital statistics database, and estimated the potential gain in life expectancy if overdose mortality were eliminated according to abridged life tables. Overdose mortality was defined as fatal unintentional drug overdoses among people using either illicit (non-prescription) drugs or prescription pharmaceuticals.

The analysis included 10,362 HIV-positive people age 20 or older in the British Columbia HIV/AIDS Drug Treatment Program clinical registry who started antiretroviral therapy (ART) between April 1996 and December 2017.

More than 80% were men and the median age was 40 years. About a quarter injected drugs. Nearly one in four had a CD4 count below 200 cells/mm3, indicating advanced immune suppression.

During the study period, 266 people (3%) died of drug overdoses, 1989 (19%) died of other causes and 117 (1%) had an undetermined cause of death. Among those who died of overdoses, 162 (61%) used narcotics (opioids) and hallucinogens; 19 (7%) used sedatives, anti-epileptic medications or psychotropic drugs; and 85 (32%) used unspecified drugs that primarily affect muscle or the respiratory system.

The researchers estimated that, overall, a 20-year-old person with HIV could expect to live 3.7 additional years in the absence of drug overdoses. But the reduction in life expectancy was greater in recent years.

The potential gain in life expectancy without overdoses was 1.5 additional years during 1996-2001, 1.9 years during 2002-2007, 3.6 years during 2008-2013 and 9.7 years in 2014-2017. That is, the loss of life expectancy was nearly fivefold higher during the recent overdose crisis. During the latter period, life expectancy for a 20 year old was 55 years, but rose to 65 years when overdose deaths were deleted.

"Survival gains, by virtue of triple-combination ART, have been dramatically reduced during the current overdose epidemic (2014-2017)," the researchers concluded. "The hazard of overdose mortality during the current overdose epidemic was nearly five times higher than [during] the harm reduction scale-up phase (2002-2007)."

"Overdose prevention and substance use treatment are necessary components of quality HIV care programs," they added.

Beyond overdose

In a related study, Dr Ayesha Appa and colleagues from the University of California at San Francisco and the San Francisco Department of Public Health looked at deaths attributable to causes other than overdoses among HIV-positive people who use drugs.

In San Francisco, people who acquired HIV via drug use have twice the mortality of HIV-positive people as a whole, they noted as background.

The researchers identified 7056 drug-related deaths among people over age 13 in San Francisco County during 2007-2018 according to the California Electronic Death Reporting System. Of these, 292 were excluded because they were found not to be due to illicit drugs. This left 223 people with HIV and 6541 HIV-negative individuals whose deaths were determined to be drug-related.

Drug-related deaths among people with HIV, compared to those among HIV-negative individuals, were more likely to involve methamphetamine (21% vs 13%), less likely to involve alcohol (26% vs 46%) and about equally likely to involve opioids (26% in both groups) or cocaine (22% vs 19%).

Both the HIV-positive and HIV-negative groups had a similar proportion of deaths due to drug overdoses (38% vs 37%) and non-infectious medical causes (37% vs 38%). But people with HIV were significantly more likely than HIV-negative people to die of drug-related acute infections (26% vs 8%). The most commonly recorded infections were sepsis (which can have multiple causes), pneumonia and endocarditis (infection of the lining of the heart). After adjusting for other factors, HIV-positive people had more than a fivefold increased risk of such deaths.

In contrast, people with HIV were less likely to have trauma or violence as a cause of death (3% vs 14%).

"Targeted efforts to combat mortality in people living with HIV who use drugs should include infection prevention efforts, such as harm reduction practices and vaccination, as well as overdose prevention," the researchers recommended.

References

St-Jean M et al. Drug overdoses are reducing the gains in life expectancy of people living with HIV (PLWH) in British Columbia, Canada. 23rd International AIDS Conference, abstract OAC0302, 2020.

Appa A et al. Beyond overdose: Comparing drug-related deaths in people with and without HIV in San Francisco. 23rd International AIDS Conference, abstract PEC0399, 2020.